Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Cash from Operations Growth (3y) (2012 - 2026)

Analysis

Charles River Laboratories International (CRL) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn 11.55%
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn 25.22%
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn 11.32%
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn 6.66%
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -42.26%
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn 15.56%
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn 50.23%
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -91.27%
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 6.66%
Mar 28, 2026 -27.85%
Dec 27, 2025 -14.35%
Sep 27, 2025 17.21%
Jun 28, 2025 11.03%
Mar 29, 2025 18.71%
Dec 28, 2024 -11.42%
Sep 28, 2024 12.95%
Jun 29, 2024 1.23%
Mar 30, 2024 -8.62%
Dec 30, 2023 16.88%
Sep 30, 2023 5.03%
Jul 1, 2023 -3.00%
Apr 1, 2023 16.83%
Dec 31, 2022 9.12%
Sep 24, 2022 -5.20%
Jun 25, 2022 4.88%
Mar 26, 2022 90.44%
Dec 25, 2021 17.88%
Sep 25, 2021 14.22%